Sale of Bertin Pharma’s pharmaceutical and biotech service businesses to Oncodesign

Sector(s)
Healthcare
Deal type
Sell your business
Date
August 2017
Countries involved
France

Client

CNIM is a French industrial engineering contractor and equipment manufacturer that operates in the sector of Environment, Energy, Defense and High Technologies

Deal

Capitalmind advised CNIM Group on the sale of Bertin Pharma’s pharmaceutical and biotech service businesses to Oncodesign

Parties

Lead team

  • Michel Degryck

    Michel Degryck

    Managing Partner France
  • Kilian de Gourcuff

    Kilian de Gourcuff

    Partner France
  • Benjamin Pasquet

    Benjamin Pasquet

    Manager France

What we did

Capitalmind supported the CNIM Group throughout the entire sale process: preparation of marketing documentation, research and selection of strategic buyers and management of carve-out issues.

About the deal

Oncodesign, completed the acquisition of the pre-clinical and clinical study activities of Bertin Pharma.
Oncodesign was founded more than 20 years ago by Dr. Philippe Genne, and is a biopharmaceutical company that specializes in ‘precision medicine’, combining medicinal chemistry, pharmacology, regulatory bioanalysis and advanced medical imaging. Oncodesign has 215 employees and subsidiaries in Canada and the United States.

By disposing of its pharma & biotech activities, the CNIM Group intends to focus on its core business, primarily in the fields of Energy, Environment, Defence and Security. Bertin Pharma currently employs 125 people and generates a turnover of 16 million euros.

Subscribe to our news & insights




Sector preference